IRADIMED CORP
No SEC Form 4 filings for $IRMD in the last 30 days.
IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.
IRADIMED CORP (IRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. irmd-20260624 0001325618 FALSE 0001325618 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): June 24, 2026 IRADIMED CORPORATIO
Scharen-Guivel Hilda Frederique sold 1,234 shares of IRADIMED CORP (IRMD) at $95.00 ($0.12M total) on 2026-06-04.
Over the past 7 days, alphai's AI scored 1 news story mentioning IRMD (IRADIMED CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IRMD coverage spans insider activity, earnings and corporate actions.
The earnings call discloses a 3870 pump production ramp, margin compression from start-up inefficiencies, and updated Q3 and full-year guidance.
Routine annual meeting voting results; no new financial guidance, deal, or enforcement action disclosed.
An insider open-market sale disclosed via Form 4; typically modest near-term signal absent additional context (e.g., 10b5-1).
Insider selling can modestly affect near-term sentiment, but this is a single, non-10b5-1 sale with limited fundamental signal.
Insider selling disclosed on SEC Form 4; likely low fundamental signal given stated 10b5-1 pre-arrangement, but can affect near-term sentiment/flow.
alphai scores every news story that mentions IRMD with an AI model for sentiment and relevance, and aggregates insider trades from IRADIMED CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.
7 min readIRADIMED CORP (IRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. irmd-20260624 0001325618 FALSE 0001325618 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): June 24, 2026 IRADIMED CORPORATIO
2 min readScharen-Guivel Hilda Frederique sold 1,234 shares of IRADIMED CORP (IRMD) at $95.00 ($0.12M total) on 2026-06-04.
2 min readScharen-Guivel Hilda Frederique sold 1,766 shares of IRADIMED CORP (IRMD) at $95.00 ($0.17M total) on 2026-06-04.
2 min readSusi Roger E. (CEO, President, Chairman) sold 924 indirectly-held shares of IRADIMED CORP (IRMD) at $91.91 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readSusi Roger E. (CEO, President, Chairman) sold 775 indirectly-held shares of IRADIMED CORP (IRMD) at $89.79 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readSusi Roger E. (CEO, President, Chairman) sold 400 indirectly-held shares of IRADIMED CORP (IRMD) at $88.68 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readIradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.
4 min readSusi Roger E. (CEO, President, Chairman) sold 7,500 indirectly-held shares of IRADIMED CORP (IRMD) at an average of $92.14 ($91.81–$92.93, $0.69M total) across 4 trades over 2026-05-26 to 2026-05-27 under a Rule 10b5-1 trading plan.
2 min readIradimed Corp (NASDAQ: IRMD) has received "Buy" ratings from all three analysts covering the stock, with a median one-year target price suggesting a nearly 34% upside. This positive outlook is driven by the company's unique position as the sole provider of non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, along with its product growth and potential for international expansion. Freedom Broker initiated coverage with a Buy rating and a $116 price target, highlighting Iradimed's profitability and specialized product portfolio.
3 min read
